Search the Newsreel

Earnings call transcript: Myriad Genetics sinks after Q2 2026 revenue miss

Myriad Genetics reported Q2 2026 revenue of $190.7 million, missing Wall Street forecasts, and posted an adjusted loss of $0.25 per share, wider than expected. Shares fell sharply by over 31% in after-hours trading. The company cut its full-year revenue guidance and suspended adjusted …

Myriad Genetics Q2 Loss Narrows; Revenue Falls 11%

(RTTNews) - Myriad Genetics, Inc. (MYGN) on Thursday reported a narrower loss for the second quarter despite a 11% decline in revenue, as last year's results were affected by a hefty goodwill impairment charge. The molecular diagnostics company also lowered its full-year 2026 revenue …

Myriad Genetics (NASDAQ:MYGN) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 28.6%

Myriad Genetics (NASDAQ:MYGN) reported Q2 CY2026 sales of $190.7 million, falling short of analyst estimates, and a non-GAAP loss of $0.25 per share, significantly below consensus. The company also lowered its full-year revenue guidance to $780 million at the midpoint from an earlier $870 …

Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates

Myriad Genetics (MYGN) Reports Q2: Everything You Need To Know Ahead Of Earnings

Myriad Genetics (MYGN) is set to report Q2 earnings this Thursday, with analysts expecting a 2.5% year-on-year revenue decline. The company missed revenue expectations last quarter, and its stock is down 9.5% over the last month, contrasting with a 4.4% average rise in the …

Myriad Genetics Inc (MYGN) Financial Health: Profitability & Balance Sheet Analysis

Myriad Genetics Inc (MYGN) has a stable financial status and high operating efficiency, ranking 93rd out of 199 companies in the Healthcare Equipment & Supplies industry with a score of 7.30. The company reported a Q4 revenue of $200.40 million, marking a 2.30% year-over-year …

Myriad Genetics rebuilt its AI platform after costs ballooned. Now, it can process documents in seconds.

Myriad Genetics significantly reduced document processing time from 10 minutes to 20 seconds per document after rebuilding its AI platform with Amazon Web Services. Initially, an internally developed AI tool, "Image Genius," proved too costly and inefficient. By leveraging AWS's Generative AI Innovation Center …

Myriad Genetics Inc (MYGN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Myriad Genetics Inc (MYGN), listing its major institutional holders such as BlackRock and Millennium Management. It also breaks down shareholder types, showing the dominance of investment advisors and hedge funds. Additionally, the report includes institutional shareholding trends …

Myriad Genetics Inc (MYGN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Myriad Genetics Inc's (MYGN) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and contains no specific dividend or stock split data. The page also includes current …

MYGN|Myriad Genetics Inc|Price:5.610|Chg%:-0.090

This article provides a detailed financial overview of Myriad Genetics Inc. (MYGN), including its latest stock price, market cap, and a comprehensive breakdown of its income statement, balance sheet, and cash flow statement. It highlights the company's recent earnings report, showing revenue and EPS …

Myriad Genetics Inc (MYGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Myriad Genetics Inc (MYGN) by business segment and by region. For FY2025, the company's revenue heavily relies on Hereditary Cancer (45.17%) and Prenatal (22.60%) segments, with most revenue generated in the United States (93.15%). The data summarizes …

Myriad Genetics (MYGN) Expected to Announce Quarterly Earnings on Thursday

Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

Myriad Genetics, Inc. SALT LAKE CITY, July 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2026 earnings conference call at 4:30 pm ET on Thursday, July 30, 2026. …

3 Reasons MYGN is Risky and 1 Stock to Buy Instead

3 Reasons MYGN is Risky and 1 Stock to Buy Instead Myriad Genetics has been treading water for the past six months, recording a small loss of 3.6% while holding steady at $5.66. The stock also fell short of the S&P 500's 8.6% gain …

Myriad Genetics stock trades sideways as investors digest recent revenue growth and precision oncolo

Myriad Genetics (NASDAQ: MYGN) stock is influenced by its revenue growth in precision oncology and plans to improve profitability. The company has shown a low double-digit percentage increase in annual revenue, reaching approximately $700 million, driven by oncology and women’s health testing. While still …

Myriad Genetics to Webcast Q2 Business Update July 30

Myriad Genetics (NASDAQ: MYGN) will release its second-quarter 2026 financial results after market close on Thursday, July 30, 2026. This will be followed by an earnings conference call at 4:30 p.m. ET, during which management will provide a financial overview and business update. A …

Myriad Genetics to Hold Second Quarter 2026 Earnings Conference Call on July 30

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

Myriad Genetics, Inc. has announced the full commercial launch of its FirstGene® Multiple Prenatal Screen. This new diagnostic test is unique in its ability to simultaneously run four prenatal genetic screens from a single blood draw as early as eight weeks gestation. The FirstGene …

Myriad Debuts FirstGene Four-in-One Prenatal Genetic Screening From Single Blood Sample

Myriad Genetics has launched FirstGene Multiple Prenatal Screen, a new laboratory test that performs four prenatal genetic screens from a single maternal blood draw as early as eight weeks of pregnancy. This innovative test combines fetal chromosome, fetal single-gene, patient carrier, and fetal RhD …

Myriad Genetics Launches New Four-in-One Prenatal Genetic Screen

Myriad Genetics has announced the full commercial launch of its FirstGene Multiple Prenatal Screen, a new laboratory test capable of performing four prenatal genetic screens from a single blood sample as early as eight weeks gestation. The test integrates fetal chromosome, fetal single-gene, patient …

Myriad's one-draw test runs four prenatal screens at 8 weeks

Myriad Genetics has launched FirstGene Multiple Prenatal Screen, a new diagnostic test capable of performing four prenatal genetic screens simultaneously from a single maternal blood draw as early as eight weeks gestation. The test integrates fetal chromosome, fetal single-gene, patient carrier, and fetal RhD …

Burning Rock and Myriad Announce Global Strategic Technology Licensing Partnership to Expand HRD Testing Worldwide

Burning Rock Biotech and Myriad Genetics have announced a global strategic technology licensing partnership to expand homologous recombination deficiency (HRD) testing worldwide. This collaboration will enhance Burning Rock's myChoice HRD Plus in China with a prostate Genomic Instability Score (prGIS) algorithm and allow Burning …

AWHL vs. MYGN: Which Women's Health Diagnostics Stock is Better Now?

This article compares Aspira Women's Health Inc. (AWHL) and Myriad Genetics, Inc. (MYGN), two companies in the women's health diagnostics sector. While AWHL focuses on gynecologic diseases and is expanding its AI-powered diagnostics portfolio, MYGN offers a more diversified portfolio across oncology, women's health, …

ETFs Investing in Myriad Genetics, Inc. Stocks

This article lists various ETFs that hold Myriad Genetics, Inc. stocks, providing key financial data for each. The funds are sorted by market value and include details such asissuer, management style, focus, expense ratio, AUM, price, and 3-year NAV total return. The ETFs offer …

Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today

Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh

Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions

Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates

Myriad Genetics (MYGN) To Report Earnings Tomorrow: Here Is What To Expect

Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for

Small-Cap Stocks: Krispy Kreme, Myriad Genetics, and Hamilton Insurance Group to Avoid - News and Statistics

Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

Myriad Genetics And 2 Other Penny Stocks To Watch Closely

Myriad Genetics Beats Q4 Expectations, Shares Surge Amid Core Franchise Growth

Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding